{"filings":[{"id":1306357,"accession_number":"0001104659-26-078327","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-06-26T21:15:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA Advisory Committee set for July 29 to review Capricor's Deramiocel BLA; PDUFA date Aug 22","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA CTGTAC Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's Deramiocel BLA for Duchenne muscular dystrophy.","PDUFA target action date remains August 22, 2026; BLA on track.","BLA supported by Phase 2 HOPE-2, HOPE-2 OLE, and Phase 3 HOPE-3 trials showing statistical significance on primary and secondary endpoints.","CEO Linda Marbán expressed confidence in the totality of evidence and commitment to urgent needs of DMD community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-26","daily_digest_url":"/daily/2026-06-26","daily_digest_rank":9},{"id":918081,"accession_number":"0001104659-26-071364","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-06-08T20:05:07+00:00","items":["5.07"],"status":"ready","headline":"Capricor shareholders fail to approve officer exculpation amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; Linda Marbán, Ph.D. re-elected with 25.5M votes for.","Ratification of Rose, Snyder & Jacobs LLP as auditor passed with 43.1M votes for.","Advisory vote on executive compensation approved (24.3M for, 6.2M against).","Non-binding vote favored '1 Year' frequency for future say-on-pay votes (29.8M of votes cast).","Amendment to certificate for officer exculpation failed: 23.5M for, 6.4M against, 13M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40292,"accession_number":"0001104659-26-059380","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-05-12T20:06:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q1 net loss $33.9M ($0.59/share); Deramiocel BLA PDUFA Aug 22, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.9M ($0.59/share) for Q1 2026 vs net loss of $24.4M ($0.53/share) in Q1 2025.","Cash balance of $278.6M as of March 31, 2026; expected to support operations through Q4 2027.","Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected soon.","Filed suit against Nippon Shinyaku/NS Pharma citing flawed pricing in distribution agreement; seeking rescission and preliminary injunction.","New Chief Commercial Officer with direct DMD experience expected to join in coming weeks; eligible for Priority Review Voucher upon approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91497,"accession_number":"0001104659-26-057221","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Capricor sues Nippon Shinyaku over failed Deramiocel launch preparations; seeks agreement rescission","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filing of complaint in NJ Superior Court alleges fundamental pricing flaw in distribution agreement making Deramiocel commercially unviable under Medicare.","Distributor accused of failing to complete gross-to-net model, mock launch, or obtain required sub-distributor consents for Capricor's cell therapy.","Pricing structure renders Deramiocel economically impracticable for Medicare, Medicaid, and private insurance patients, per complaint.","Capricor seeks rescission of distribution agreement, declaratory judgment, and preliminary injunction ahead of PDUFA date of August 22, 2026.","FDA Priority Review for Deramiocel remains on track; Capricor states it is building commercial readiness independently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101613,"accession_number":"0001104659-26-027037","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor FY2025 net loss $105M; Deramiocel PDUFA date Aug 22, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.2M in Q4 2025 ($0.62/sh) and $105.0M for FY2025 ($2.26/sh).","Revenue was $0 in Q4 and FY2025, vs $11.1M and $22.3M in prior-year periods, as Nippon Shinyaku milestones fully recognized.","Cash, equivalents and marketable securities $318.1M at Dec 31, 2025, up from $151.5M; expected to fund operations through 2027.","BLA for Deramiocel in Duchenne muscular dystrophy under FDA review; PDUFA target date August 22, 2026.","Phase 3 HOPE-3 trial met primary endpoint (PUL v2.0, p=0.03) and key cardiac endpoint (LVEF, p=0.04)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101612,"accession_number":"0001104659-26-025657","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts CRL for Deramiocel BLA; new PDUFA date August 22, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA resumed review of Deramiocel BLA for Duchenne muscular dystrophy cardiomyopathy after lifting CRL.","Submission classified as Class 2 resubmission; PDUFA target action date set for August 22, 2026.","BLA supported by positive HOPE-3 Phase 3 trial meeting primary and all secondary endpoints.","Company expects to be eligible for a Priority Review Voucher upon potential approval.","FDA has not identified any review issues in its response to Capricor at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117963,"accession_number":"0001104659-25-118934","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Capricor Therapeutics prices $150M public offering of 6M shares at $25/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering 6,000,000 shares at $25.00 per share; expected gross proceeds ~$150M.","Underwriters granted 30-day option to purchase up to 900,000 additional shares.","Net proceeds for product candidate development, manufacturing, working capital, and corporate purposes.","Joint book-running managers: Piper Sandler & Co. and Oppenheimer & Co.; co-manager: H.C. Wainwright & Co.","Offering expected to close on or about December 8, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117962,"accession_number":"0001104659-25-117981","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Capricor provides HOPE-3 trial update via slide presentation, no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 7.01 with slide presentation dated Dec 3, 2025 on HOPE-3 Phase 3 top-line results.","Slide presentation contains no specific efficacy or safety numbers in the attached exhibit.","Company held conference call; full slides available on investor website.","No materially new financial or clinical information beyond prior top-line announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117961,"accession_number":"0001104659-25-117947","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Capricor Therapeutics Announces Positive Phase 3 HOPE-3 Results for Deramiocel in Duchenne Muscular Dystrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint PUL v2.0 met with 54% slowing of progression (p=0.029) in 105 evaluable patients.","Key secondary cardiac endpoint LVEF showed 91% slowing of decline (p=0.041) in 83 evaluable patients.","Study enrolled 106 participants (average age 15) across 20 U.S. sites; over 75% had diagnosed cardiomyopathy.","Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.","Company plans to submit response to Complete Response Letter incorporating HOPE-3 data following prior FDA alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117960,"accession_number":"0001104659-25-109119","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor reports Q3 net loss $24.6M; HOPE-3 topline DMD data expected in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.6M ($0.54/share) vs $12.6M ($0.38) in Q3 2024; operating expenses $26.3M, up 72%.","Revenue $0 vs $2.3M in prior year; prior revenue from Nippon Shinyaku milestones now fully recognized.","Cash $98.6M as of Sept 30, down from $151.5M at Dec 31, 2024; runway into Q4 2026.","Topline results from HOPE-3 Phase 3 trial of Deramiocel for Duchenne cardiomyopathy expected in Q4 2025.","FDA supported submitting HOPE-3 results for BLA resubmission (Type A meeting); PLI completed with all 483 observations addressed."],"consensus_eps_estimate":-0.5585,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134413,"accession_number":"0001558370-25-011047","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q2 net loss $25.9M; FDA accepts all PLI observations; StealthX vaccine enters clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.9M ($0.57 per share) for Q2 2025 vs $11.0M ($0.35) in Q2 2024; revenue $0 vs $4.0M.","Cash, equivalents and securities $122.8M at June 30, 2025; expected to fund operations into Q4 2026.","FDA accepted all 483 observations from Pre-License Inspection; Type A meeting scheduled for August 2025 to discuss Deramiocel BLA resubmission.","FDA cleared IND for StealthX exosome-based vaccine; NIAID-initiated Phase 1 trial initiated in August 2025; first dosing imminent.","HOPE-3 Phase 3 topline data expected Q4 2025; Orphan Drug Designation granted for Deramiocel in Becker muscular dystrophy."],"consensus_eps_estimate":-0.4783,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134412,"accession_number":"0001558370-25-009186","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Capricor receives FDA Complete Response Letter for Deramiocel BLA; plans Q3 2025 resubmission with HOPE-3 data","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL stating BLA lacks substantial evidence of effectiveness; additional clinical data needed.","Capricor plans to resubmit BLA in Q3 2025 with data from ongoing Phase 3 HOPE-3 trial (104 patients, topline Q3 2025).","FDA confirmed review clock restarts upon resubmission; Type A meeting offered to discuss path forward.","CRL referenced outstanding CMC items, but Capricor believes most were addressed; not reviewed due to CRL timing.","Prior to CRL, BLA had Priority Review, successful pre-licensure inspection, and mid-cycle review completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151236,"accession_number":"0001558370-25-008145","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Capricor stockholders approve 2025 Equity Incentive Plan (3.5M shares plus 5% annual increase)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved 2025 Equity Incentive Plan (3.5M shares reserved) with ~54% of votes cast in favor (9.7M FOR, 8.2M AGAINST).","Plan includes annual evergreen increase of 5% of outstanding shares from 2026 through 2035.","Rose, Snyder & Jacobs LLP ratified as independent auditor for FY2025.","Say-on-pay advisory vote passed with ~92% in favor (16.4M FOR, 1.5M AGAINST).","30.55M shares present (66.9% of outstanding) at annual meeting on May 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151235,"accession_number":"0001558370-25-007574","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q1 net loss $24.4M; deramiocel BLA PDUFA Aug 31, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.4M ($0.53/sh) vs $9.8M loss ($0.31/sh) in Q1 2024; revenue $0 vs $4.9M.","Cash and equivalents $144.8M as of Mar 31, 2025; expected to fund operations into 2027.","FDA accepted BLA for deramiocel in DMD-cardiomyopathy with priority review; PDUFA date Aug 31, 2025.","Mid-cycle review with FDA completed; no significant deficiencies identified; advisory committee planned.","Appointed Dr. Michael Binks as CMO; NIAID plans to initiate StealthX vaccine Phase 1 trial in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151234,"accession_number":"0001558370-25-004605","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Earl Collier not standing for re-election at May 22, 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Earl Collier will not stand for re-election to the Board at the May 22, 2025 Annual Meeting.","His departure is not due to any disagreement with the Company's operations, policies, or practices.","Company plans to enter into a consulting agreement with Collier for strategic advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170126,"accession_number":"0001558370-25-003304","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Therapeutics reports Q4 net loss $7.1M, BLA for deramiocel accepted with PDUFA Aug 31, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted BLA for deramiocel to treat DMD cardiomyopathy; Priority Review, PDUFA date August 31, 2025.","HOPE-2 OLE data showed 52% slowing of disease progression over 3 years vs external comparator (p=0.019).","Cash balance $151.5M at Dec 31, 2024; received $10M milestone from Nippon Shinyaku in Jan 2025; cash runway into 2027.","Q4 2024 revenue $11.1M (vs $12.1M Q4 2023); net loss $7.1M ($0.16/share) vs $0.8M loss ($0.02/share).","Full year 2024 net loss $40.5M ($1.15/share) vs $22.3M ($0.83/share) in 2023; operating expenses $64.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170125,"accession_number":"0001558370-25-002097","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Capricor's BLA for deramiocel for DMD cardiomyopathy with Priority Review, PDUFA Aug 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for deramiocel (cell therapy) to treat Duchenne muscular dystrophy cardiomyopathy.","Priority Review granted; PDUFA target date August 31, 2025.","FDA has not identified any potential review issues at this time.","If approved, deramiocel would be first approved therapy for DMD cardiomyopathy.","Supports Phase 2 HOPE-2 and OLE trials vs. natural history data from FDA-funded dataset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170124,"accession_number":"0001558370-25-000010","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Capricor submits BLA for deramiocel to FDA for DMD cardiomyopathy; receives $10M milestone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA for deramiocel (cell therapy) submitted to FDA for DMD cardiomyopathy on Jan 2, 2025.","Submission triggers $10M milestone payment from partner Nippon Shinyaku to Capricor.","If approved, deramiocel would be first approved therapy for DMD cardiomyopathy.","Priority review requested; if granted, review timeline reduced to ~6 months from acceptance.","Deramiocel holds Orphan Drug, RMAT (US), ATMP (EU) designations; potential PRV if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187138,"accession_number":"0001558370-24-015519","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor reports Q3 net loss $12.6M; starts BLA for deramiocel, signs $715M European deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $12.6M ($0.38/sh) vs $6.4M ($0.25/sh); revenue $2.3M vs $6.2M.","Began rolling BLA submission for deramiocel (DMD cardiomyopathy) Oct 2024; full submission expected year-end; PDUFA H2 2025.","Signed binding term sheet with Nippon Shinyaku for Europe: $20M upfront, up to $715M milestones plus double-digit revenue share.","Public offering net proceeds ~$80.8M; cash $85M at Sep 30; runway into 2027.","Nippon Shinyaku purchased ~$15M of CAPR stock at 20% premium."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":11139956.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187137,"accession_number":"0001558370-24-013357","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Capricor Therapeutics prices ~$75M public offering of 4.4M shares at $17/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$75M from 4,412,000 shares at $17.00/sh; underwriters have 30-day option for up to 661,800 additional shares.","Offering expected to close October 18, 2024; Piper Sandler and Oppenheimer act as joint book-running managers.","Net proceeds to fund continued product candidate development, manufacturing, working capital, and general corporate purposes.","Offering made under effective Form S-3 shelf registration; prospectus supplement filed October 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187136,"accession_number":"0001558370-24-013344","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Capricor files BLA for deramiocel in DMD cardiomyopathy; reports ~$85M cash as of Sept 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA for deramiocel filed Oct 2024 seeking full approval for DMD cardiomyopathy; full submission by year-end 2024.","HOPE-2/OLE data vs natural history supports BLA; HOPE-3 Cohorts A+B combined as post-approval study, Cohort A unblinding paused.","StealthX SARS-CoV-2 vaccine selected for Project NextGen; manufacturing ongoing, delivery to NIAID by end-2024.","Private placement to Nippon Shinyaku: 2.8M shares at $5.36 for ~$15M; ATM sales: 5.5M shares at $9.84 avg for ~$53.9M.","Preliminary cash balance ~$85M as of Sept 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187135,"accession_number":"0001558370-24-013207","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Capricor initiates rolling BLA submission to FDA for deramiocel in DMD cardiomyopathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Rolling submission started Oct 9, 2024; plans to complete by end of 2024.","BLA seeks full approval for deramiocel to treat all DMD cardiomyopathy patients.","No approved treatments currently exist for DMD cardiomyopathy.","Application may be eligible for priority review by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203654,"accession_number":"0001558370-24-012983","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Capricor Therapeutics to file BLA for deramiocel in DMD cardiomyopathy; rolling submission in Oct 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Plans to file BLA for deramiocel to treat DMD cardiomyopathy based on existing cardiac and natural history data; rolling submission begins Oct 2024 with full submission by year-end 2024.","BLA supported by Phase 2 HOPE-2 and HOPE-2 OLE data vs natural history from Vanderbilt and Cincinnati Children's.","Will combine Cohorts A and B of Phase 3 HOPE-3 as a post-approval study; no unblinding of Cohort A as previously planned for Q4 2024.","Deramiocel has FDA Orphan Drug, RMAT, and Rare Pediatric Disease designations (PRV eligible upon approval).","No approved therapies for DMD cardiomyopathy; deramiocel targets leading cause of death in Duchenne."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203653,"accession_number":"0001558370-24-012836","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Capricor signs binding term sheet with Nippon Shinyaku for European deramiocel rights; $15M equity + $20M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nippon Shinyaku to commercialize deramiocel in EU, UK and other European countries; Capricor receives double-digit revenue share.","Up to $715M in milestone payments plus $20M upfront upon definitive agreement (expected Q4 2024); combined milestones now ~$1.5B.","Private placement of 2.8M shares at $5.36 (20% premium to 60-day VWAP) raises ~$15M; proceeds extend cash runway into 2026.","Capricor to develop and manufacture deramiocel; meeting with EMA planned to discuss European expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203652,"accession_number":"0001558370-24-011350","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q2 2024: $11M loss, positive FDA pre-BLA meeting, DMD trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.0M ($0.35/sh) in Q2 2024 vs $7.4M ($0.29) in Q2 2023; revenue $4.0M.","Cash $29.5M at June 30, 2024 (down from $39.5M at Dec 31); raised $2.1M via ATM at $6.46/sh.","Positive pre-BLA meeting with FDA for deramiocel; HOPE-3 Phase 3 fully enrolled (105 subjects).","Top-line data from HOPE-3 Cohort A expected Q4 2024; 3-year HOPE-2 OLE showed +3.7 point PUL benefit.","Cash runway into Q1 2025; added to Russell 2000/3000 indexes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":8878315.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220178,"accession_number":"0001558370-24-008313","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Capricor Therapeutics increases authorized common shares from 50M to 100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment at May 14, 2024 annual meeting.","Certificate of Amendment filed with Delaware on May 15, 2024, effective same day.","Authorized common stock increased to 100 million shares (previously 50 million)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220177,"accession_number":"0001558370-24-008310","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Capricor shareholders approve doubling authorized shares to 100M and elect all nine director nominees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to increase authorized common shares from 50M to 100M approved (12.3M for, 8.7M against).","All nine director nominees elected, including CEO Linda Marbán and Frank Litvack.","Ratification of Rose, Snyder & Jacobs as auditor for FY 2024 approved (20.3M for).","Non-binding advisory vote on executive compensation approved (9.2M for, 2.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220176,"accession_number":"0001558370-24-007958","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q1 net loss $9.8M; HOPE-3 Cohort A fully enrolled for Q4 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.8M ($0.31/share) vs $7.8M loss prior year; revenue $4.9M from Nippon Shinyaku milestone.","Phase 3 HOPE-3 Cohort A fully enrolled (61 patients); top-line results expected Q4 2024.","Positive Type-B CMC FDA meeting confirmed manufacturing comparability between facilities.","Received $10M milestone from Nippon Shinyaku; $90M pre-approval milestones remain possible.","Cash $39.9M stable; runway into Q1 2025, excluding additional milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":4906877.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220175,"accession_number":"0001558370-24-006020","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Capricor presents CAP-1002 DMD program update: FDA alignment on BLA path; HOPE-3 topline data Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment complete in HOPE-3 Phase 3 Cohort A (N=61); topline 12-month data expected Q4 2024.","FDA agreed HOPE-3 Cohort A is sufficient to support BLA; non-clinical comparability shown with two potency assays.","San Diego facility to be used for commercial manufacturing upon potential approval; commercial planning underway with Nippon Shinyaku.","Upcoming Type-C meeting to discuss pre-BLA meeting and rolling BLA submission schedule.","Estimated U.S. DMD annual product revenue opportunity >$1.5B; target addressable patients ~7,500-10,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239877,"accession_number":"0001558370-24-002183","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor reports Q4 net loss $0.8M; Phase 3 DMD trial on track for top-line data Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $0.8M ($0.02/share) vs $7.7M ($0.31) in Q4 2022; revenue $12.1M from Nippon Shinyaku agreement.","Cash $39.5M at Dec 31, 2023; $10M milestone payment from Nippon Shinyaku received Jan 2024.","Enrollment complete in Cohort A of Phase 3 HOPE-3 trial for CAP-1002 in DMD; positive interim futility analysis.","Cohort B enrollment underway, expected to complete Q2 2024; top-line data from Cohort A expected Q4 2024.","Selected for Project NextGen; NIAID to fund Phase 1 trial of StealthX exosome-based COVID-19 vaccine in late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":25178066.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239876,"accession_number":"0001558370-24-000197","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Capricor receives $10M milestone from Nippon Shinyaku; HOPE-3 trial continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milestone payment of $10.0 million received from Nippon Shinyaku under 2022 commercialization agreement.","Payment triggered by favorable interim futility analysis from Data Safety Monitoring Board for HOPE-3 trial.","DSMB recommended continuation of HOPE-3 trial as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257395,"accession_number":"0001558370-23-019717","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Capricor Phase 3 HOPE-3 trial of CAP-1002 in DMD passes interim futility analysis; milestone payment triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive interim futility analysis from DSMB; trial to continue as planned.","Triggers first milestone payment under U.S. agreement with Nippon Shinyaku.","HOPE-3 Cohort A enrollment complete; topline data expected Q4 2024.","Company plans to request FDA meeting in Q1 2024 for expedited approval pathways.","Cohort B enrollment initiated; ~102 subjects total across both cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257394,"accession_number":"0001558370-23-019019","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor completes HOPE-3 enrollment; Q3 net loss $6.4M, cash $28.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed targeted enrollment for HOPE-3 Phase 3 trial of CAP-1002 in Duchenne muscular dystrophy; interim futility analysis expected Q4 2023.","FDA affirmed alignment on HOPE-3 design; BLA submission planned supported by Cohort A results.","Q3 revenue $6.2M (from Nippon Shinyaku upfront recognition) vs $1.6M prior year; net loss $6.4M flat YoY.","Cash $28.5M at Sept 30; subsequent $23M registered direct offering with Nippon Shinyaku extends runway into 2025.","Appointed Michael Kelliher (Amgen/Horizon) to Board of Directors; advancing StealthX exosome platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":13089977.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274727,"accession_number":"0001558370-23-016171","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Capricor raises $23M in registered direct offering of stock and warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gross proceeds ~$23M from 4,935,621 shares plus warrants at $4.66/unit.","Warrants exercisable at $5.70/share for 7 years, beginning 6 months after issuance.","Investors include Nippon Shinyaku and Highbridge Capital Management.","Net proceeds to fund R&D, manufacturing, working capital; expected to fund HOPE-3 Phase 3 topline data readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274726,"accession_number":"0001558370-23-016149","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Capricor announces positive FDA Type-B meeting confirming Phase 3 path to BLA for CAP-1002 in DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on HOPE-3 trial design; key endpoints unchanged; BLA submission targeted for 2025.","HOPE-3 enrollment ~90% complete (52 of ~58 patients dosed); interim analysis expected Q4 2023.","Topline data for HOPE-3 expected Q4 2024; BLA supported by product from Los Angeles site.","San Diego site work continues for potential commercial demand; CAP-1002 holds Orphan Drug and RMAT designations.","Company eligible for Priority Review Voucher if CAP-1002 receives FDA approval for DMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274725,"accession_number":"0001558370-23-015482","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Capricor Therapeutics appoints Michael Kelliher to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Kelliher appointed to Board effective September 1, 2023; Board size increased from 8 to 9.","Kelliher is Group VP of M&A and Business Development at Horizon Therapeutics; 20+ years biotech/pharma experience.","Receives initial nonstatutory stock option for 115,000 shares vesting over 3 years (25% at 1 year, then monthly).","Will enter standard indemnification agreement; no committees assigned initially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274724,"accession_number":"0001558370-23-013590","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor reports Q2 net loss $7.4M; HOPE-3 DMD trial on track for Q4 2023 interim analysis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $37.8M as of June 30, down from $41.4M Dec 31, 2022.","Q2 revenue $3.9M from Nippon Shinyaku upfront recognition vs. $0 in prior year; operating expenses $11.7M vs $7.3M.","HOPE-3 Phase 3 DMD trial: 48 of ~68 patients randomized across 17 sites; enrollment completion and interim analysis expected Q4 2023.","Held FDA Type-B clinical meeting to discuss CAP-1002 BLA pathway; final minutes awaited.","Raised ~$2.1M net via ATM at avg $4.87/share; cash runway through Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":6904163.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274723,"accession_number":"0001558370-23-012106","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Capricor expands board to 8, appoints former Novartis BD executive Philip Gotwals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 8 directors; Philip Gotwals, Ph.D. elected effective July 21, 2023.","Gotwals brings nearly 30 years biotech experience, most recently Global Head of BD at Novartis.","Received initial grant of nonstatutory stock option to purchase 115,000 shares, vesting over 4 years.","Will not initially serve on any committee; standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274722,"accession_number":"0001558370-23-011854","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Capricor board member Manzo resigns; appoints Paul Auwaerter, M.D. to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Louis Manzo resigned from board effective July 11, 2023, with no disagreement over operations.","Manzo entered a consulting agreement to perform investor relations services for Capricor.","Paul Auwaerter, M.D. appointed to board; receives initial option grant of 115,000 shares vesting over 3 years.","Auwaerter is Clinical Director at Johns Hopkins Division of Infectious Diseases with over 30 years experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292040,"accession_number":"0001558370-23-011153","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K/A","filed_at":"2023-06-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Capricor files Certificate of Correction voiding amendment to exculpation provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Correction filed June 15, 2023 voids the Certificate of Amendment filed June 13, 2023.","The amendment to limit officer liability did not receive required stockholder approval.","Company's Certificate of Incorporation remains unchanged from pre-June 13, 2023 version."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292039,"accession_number":"0001558370-23-011151","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K/A","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Capricor amends 8-K: officer exculpation proposal did not pass, correcting prior report","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 4 (officer exculpation amendment) failed: 5,037,656 for, 1,816,404 against, 103,335 abstain, 9,390,464 broker non-votes.","All other proposals passed: directors elected, auditor ratified, executive compensation approved.","Original 8-K incorrectly reported Proposal 4 as passing; this amendment corrects the vote outcome.","Annual meeting held June 12, 2023; 16,347,859 shares voted of 25,269,926 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292043,"accession_number":"0001558370-23-011050","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Capricor Therapeutics amends charter to extend officer exculpation under DGCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the amendment on June 12, 2023.","Certificate of Amendment filed with Delaware Secretary of State on June 13, 2023, effective same day.","Amendment extends exculpation of monetary liability to officers for breach of fiduciary duty, as permitted by DGCL Section 102(b)(7).","Previously only directors were exculpated; change aligns with Delaware law update effective August 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292042,"accession_number":"0001558370-23-011046","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Capricor Therapeutics shareholders elect all seven director nominees and approve all proposals at 2023 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected: Litvack, Marbán, Musket, Dunbar, Manzo, Collier, Es Sabar (FOR votes 4.9M-5.9M; ~9.4M broker non-votes).","Rose, Snyder & Jacobs LLP ratified as auditor for FY2023: 14.6M FOR, 0.4M AGAINST, 1.3M abstain.","Non-binding advisory vote on named executive officer compensation approved: 4.3M FOR, 2.4M AGAINST, 0.2M abstain.","Amendment to Certificate of Incorporation for officer exculpation approved: 5.0M FOR, 1.8M AGAINST, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292041,"accession_number":"0001558370-23-009363","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q1 2023 net loss $7.8M; HOPE-3 DMD trial interim analysis on track for Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M ($0.31 per share) flat YoY; revenue $3.0M from Nippon Shinyaku deal vs zero prior year.","Cash, equivalents and marketables $45.2M; runway into Q4 2024, excludes milestone payments.","HOPE-3 Phase 3 for CAP-1002 in DMD: 13 active sites, targeting full enrollment by H2 2023, interim analysis Q4 2023.","24-month HOPE-2 open-label extension data planned for presentation in Q2 2023.","Received $12M upfront from Japan partner Nippon Shinyaku; potential milestones up to ~$89M plus revenue share."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2986696.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312788,"accession_number":"0001558370-23-003866","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor reports Q4 2022 net loss $7.7M ($0.31/share); expands Nippon Shinyaku deal to Japan for $12M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $1.0M (Nippon Shinyaku upfront recognition) vs $0; net loss $7.7M vs $6.2M in Q4 2021.","Full-year 2022 net loss $29.0M ($1.18/share) vs $20.0M ($0.87/share); cash $41.4M as of Dec 31, 2022.","HOPE-3 Phase 3 trial for CAP-1002 in DMD >30% enrolled; interim analysis expected Q4 2023.","Japan partnership with Nippon Shinyaku: $12M upfront, up to $89M milestones, double-digit net revenue share.","Cash runway projected into Q4 2024, including $12M Japan upfront expected in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312787,"accession_number":"0001558370-23-001454","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Capricor partners with Nippon Shinyaku for CAP-1002 in Japan; $12M upfront, up to $89M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive Japan commercialization and distribution agreement for CAP-1002 in Duchenne muscular dystrophy.","Capricor receives $12M upfront plus up to ~$89M in development and sales milestones.","Capricor also gets a meaningful double-digit percentage of product revenue from Japan sales.","Capricor retains marketing authorization and clinical development; Nippon Shinyaku handles distribution.","Follows a similar U.S. deal with Nippon Shinyaku signed in January 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331308,"accession_number":"0001558370-22-017398","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q3 2022 net loss $6.4M, cash $46.6M; HOPE-3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.6M from Nippon Shinyaku upfront recognition; net loss $0.26/shr vs $0.17/shr a year ago.","Cash and securities $46.6M as of Sept 30, 2022, up from $34.9M at year-end 2021.","Raised ~$1.9M through ATM at avg $5.72/shr; cash runway expected into Q2 2024.","HOPE-3 Phase 3 for CAP-1002 in DMD enrollment progressing; interim analysis expected mid-2023.","Positive one-year HOPE-2 open label extension data presented at WMS 2022; new StealthX exosome vaccine data shown."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":1591566.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348847,"accession_number":"0001558370-22-013054","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Capricor Q2 net loss $7.1M; CAP-1002 Phase 3 trial underway, cash $51.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.1M ($0.29/share) vs $4.7M ($0.21/share) in Q2 2021.","Cash & equivalents $51.4M at June 30, 2022, up from $34.9M at Dec. 31, 2021.","First patient dosed in HOPE-3 pivotal Phase 3 trial of CAP-1002 for late-stage Duchenne muscular dystrophy.","Positive one-year HOPE-2 OLE data showed statistically significant skeletal muscle improvement (PUL v2.0, p=0.02).","Requesting FDA meeting to discuss CAP-1002 approval pathway; cash runway into Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348846,"accession_number":"0001558370-22-010821","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Capricor dosed first patient in Phase 3 HOPE-3 trial of CAP-1002 for Duchenne MD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in randomized, double-blind, placebo-controlled HOPE-3 trial enrolling ~70 patients in U.S.","CAP-1002 is a cell therapy for late-stage Duchenne muscular dystrophy; Phase 2 data showed up to 70% slowing of upper limb function loss.","Primary endpoint is Performance of the Upper Limb 2.0; RMAT and Orphan Drug designations support regulatory pathway.","Nippon Shinyaku partnership provides funding and commercialization rights in U.S.; Capricor holds rest-of-world rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365652,"accession_number":"0001558370-22-010449","cik":1133869,"company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Capricor provides top-line update from HOPE-2 open label extension trial","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Capricor reported top-line results from HOPE-2 OLE (1-year data) via slide presentation on June 27, 2022.","The slide presentation was made available on the company's website; specific data not detailed in the filing.","No numerical results or endpoint data are included in the filed exhibit; only a title slide is reproduced.","The update was disclosed under Regulation FD; a conference call was held the same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1674811990.200412,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-29T23:59:59+00:00|365652"}